The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F24%3A10465851" target="_blank" >RIV/00216208:11160/24:10465851 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/24:10465851 RIV/00179906:_____/24:10465851
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwTIe~n7CY" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QwTIe~n7CY</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10557-023-07455-y" target="_blank" >10.1007/s10557-023-07455-y</a>
Alternative languages
Result language
angličtina
Original language name
The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia
Original language description
Patients suffering from familial hypercholesterolemia (FH) have a high risk of thrombotic cardiovascular events. The aim of the study was to analyse the impact of different therapies including convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9ab) on platelet aggregation in FH. PCSK9ab have been administered in 12 of 15 patients while 8 patients were also undergoing lipid apheresis. Blood samples from all patients including pre- and post-apheresis period were tested for platelet aggregation triggered by 7 inducers, and the effect of 3 clinically used drugs (acetylsalicylic acid, ticagrelor and vorapaxar) was compared as well. Although apheresis decreased the reactivity of platelets in general, platelet responses were not different between non-apheresis patients treated with PCSK9ab and apheresis patients (post-apheresis values) with the exception of ristocetin. However, when compared to age-matched healthy population, FH patients had significantly lower platelet aggregation responses to 4 out of 7 used inducers and higher profit from 2 out of 3 used antiplatelet drugs even after exclusion of FH patients regularly receiving conventional antiplatelet treatment.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/NU21J-02-00021" target="_blank" >NU21J-02-00021: Differences in parameters of platelets aggregation and blood coagulation between healthy individuals and patients with metabolic diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cardiovascular Drugs and Therapy
ISSN
0920-3206
e-ISSN
1573-7241
Volume of the periodical
38
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
959-970
UT code for WoS article
000980357300001
EID of the result in the Scopus database
2-s2.0-85156105870